Targets › CRLF2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2030.
Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. (UniProt, Q9HC73)
Open in Phaseline: the race on CRLF2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | TSLPR-CART Anti-CRLF2 chimeric antigen receptor T cell therapy | CRLF2 | Phase 1 | B-All | Jun 2030 |
B-All (1)
mixed (1)
National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.